Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Main Article Content

Christopher Bunick
Neal Bhatia
James Del Rosso
Zoe Draelos
Lawrence Eichnfield
Leon Kircik
Mark Lebwohl
Melinda Gooderham
Lawrence Green
Adelaide Hebert
Ronald Vender
Matthew Zirwas
Eric Simpson
Linda Stein Gold
Melissa Seal
Scott Snyder
David Osborne
Patrick Burnett
Robert Higham
David Chu
David Berk


roflumilast cream, roflumilast foam, psoriasis, seborrheic dermatitis, atopic dermatitis, local tolerability


1. Eastman WJ, et al. Cutis 2014;94:46–53.

2. Danby SG, et al. J Dermatolog Treat 2022;33:685–698.

3. Lessmann H, et al. Contact Dermatitis 2005;53:247–259.

4. Zirwas MJ, et al. JAMA Dermatol 2023;159:613–620. 5. ZORYVE (roflumilast) cream prescribing information. Westlake Village, CA: Arcutis Biotherapeutics, Inc; July, 2022. 6. Lebwohl MG, et al. JAMA 2022;328:1073–1084.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>